G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)

Market Cap	1.82B -40.8%
Revenue (ttm)	215.61M -26.7%
Net Income	86.25M -35.9%
EPS	1.25 -36.0%
Shares Out	63.72M
PE Ratio	22.81
Forward PE	n/a
Dividend	1.08 (3.61%)
Ex-Dividend Date	Jul 28, 2026

Volume	6,020
Open	28.10
Previous Close	28.50
Day's Range	28.10 - 28.40
52-Week Range	27.35 - 48.61
Beta	-0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About G&E Herbal Biotechnology

G&E Herbal Biotechnology Co., Ltd. engages in manufacturing and wholesale of western and chinese medicine, cosmetics, intellectual property rights, biotechnology services, medical device, and other unclassified food products in Taiwan. It offers HepaGent capsules, a liver protective agent; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as lubricants. G&E Herbal Biotechnology Co., Ltd. was fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 43
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4911

Financial Performance

In 2025, G&E Herbal Biotechnology's revenue was 309.13 million, an increase of 24.13% compared to the previous year's 249.03 million. Earnings were 139.20 million, an increase of 36.38%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 15, 2026

Data Sources Report a data error